Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2021

Open Access 01-12-2021 | Cushing's Syndrome | Case report

A rare case of ectopic ACTH syndrome with rhabdomyolysis

Authors: Wei Qiang, Sucai Song, Tianjun Chen, Zhe Wang, Jun Feng, Jiaojiao Zhang, Hui Guo

Published in: BMC Endocrine Disorders | Issue 1/2021

Login to get access

Abstract

Background

Manifestations of hypokalaemia in ectopic adrenocorticotropic hormonesyndrome(EAS) vary from mild muscle weakness to life-threatening arrhythmia. Herein, we present a rare case of EAS with concomitant rhabdomyolysis(RM) as a result of intractable hypokalaemia.

Case presentation

A 64-year-old man was admitted for limb weakness and facial hyperpigmentation for 2 weeks. Lab tests revealed intractable hypokalaemia (lowest at 1.8 mmol/L) and metabolic alkalosis. The diagnosis of RM was based on a creatine kinase(CK)level of 5 times the upper limit. The elevated CK and myohemoglobin (Mb) levels returned to within the normal range after the alleviation of hypokalaemia. The patient was diagnosed with ACTH-dependent Cushing’s syndrome (CS) based on unsuppressed serum cortisol after a low-dose dexamethasone suppression test(LDDST) and remarkably elevated ACTH levels. The diagnosis of EAS was made based on the results of a high-dose dexamethasone suppression test(HDDST) and bilateral inferior petrosal sinus sampling(BIPSS). Multiple lymph nodes in the left supraclavicular fossa, right root of neck, mediastinum and bilateral hili of the lung were found with abnormal uptake of 68Ga-DOTA-NOC. Mediastinoscopic lymph node biopsy was performed. The pathological diagnosis was small-cell and large-cell neuroendocrine carcinoma with positive ACTH staining. The patient was prescribed mifepristone and received one cycle of chemotherapy. The patient could not tolerate subsequent chemotherapy and died of dyscrasia.

Conclusions

RM is a rare complication of EAS with insidious onset and atypical clinical manifestations. Serum potassium levels should be vigilantly monitored to avoid RM in EAS.
Literature
1.
go back to reference Ferone D, Albertelli M. Ectopic Cushing and other paraneoplastic syndromes in thoracic neuroendocrine tumors. Torac Surg Clin. 2014;24(3):277–83.CrossRef Ferone D, Albertelli M. Ectopic Cushing and other paraneoplastic syndromes in thoracic neuroendocrine tumors. Torac Surg Clin. 2014;24(3):277–83.CrossRef
2.
go back to reference Isidori AM, Lenzi A. Ectopic ACTH syndrome. Arquivos brasileiros de endocrinologia emetabologia. 2007;51(8):1217-25. Isidori AM, Lenzi A. Ectopic ACTH syndrome. Arquivos brasileiros de endocrinologia emetabologia. 2007;51(8):1217-25.
3.
go back to reference Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A commonclassification framework for neuroendocrine neoplasms: an International Agencyfor Research on Cancer (IARC) and World Health Organization (WHO) expertconsensus proposal. Mod Pathol. 2018;31(12):1770–86.CrossRef Rindi G, Klimstra DS, Abedi-Ardekani B, Asa SL, Bosman FT, Brambilla E, et al. A commonclassification framework for neuroendocrine neoplasms: an International Agencyfor Research on Cancer (IARC) and World Health Organization (WHO) expertconsensus proposal. Mod Pathol. 2018;31(12):1770–86.CrossRef
4.
go back to reference Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab. 2006;91(2):371–7.CrossRef Isidori AM, Kaltsas GA, Pozza C, Frajese V, Newell-Price J, Reznek RH, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab. 2006;91(2):371–7.CrossRef
5.
go back to reference Isidori AM, Kaltsas GA, Mohammed S, Morris DG, Jenkins P, Chew SL, et al. Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab. 2003;88(11):5299–306.CrossRef Isidori AM, Kaltsas GA, Mohammed S, Morris DG, Jenkins P, Chew SL, et al. Discriminatory value of the low-dose dexamethasone suppression test in establishing the diagnosis and differential diagnosis of Cushing’s syndrome. J Clin Endocrinol Metab. 2003;88(11):5299–306.CrossRef
6.
go back to reference Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. Lancet. 2015;386(9996):913–27.CrossRef Lacroix A, Feelders RA, Stratakis CA, Nieman LK. Cushing’s syndrome. Lancet. 2015;386(9996):913–27.CrossRef
7.
go back to reference Huang Q, Muzitansky A, Mark EJ. Pulmonary neuroendocrine carcinomas. A review of 234 cases and a statistical analysis of 50 cases treated at one institution using a simple clinicopathologic classification. Arch Pathol Lab Med. 2002;126(5):545–53.CrossRef Huang Q, Muzitansky A, Mark EJ. Pulmonary neuroendocrine carcinomas. A review of 234 cases and a statistical analysis of 50 cases treated at one institution using a simple clinicopathologic classification. Arch Pathol Lab Med. 2002;126(5):545–53.CrossRef
8.
go back to reference Broersen LHA, Jha M, Biermasz NR, Pereira AM, Dekkers OM. Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis. Pituitary. 2018;21(6):631–41.CrossRef Broersen LHA, Jha M, Biermasz NR, Pereira AM, Dekkers OM. Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis. Pituitary. 2018;21(6):631–41.CrossRef
9.
go back to reference Allison RC, Bedsole DL. The other medical causes of rhabdomyolysis. Am J MedSci. 2003;326(2):79–88.CrossRef Allison RC, Bedsole DL. The other medical causes of rhabdomyolysis. Am J MedSci. 2003;326(2):79–88.CrossRef
10.
go back to reference Rees JH. Paraneoplastic syndromes: when to suspect, how to confirm, and howto manage. J Neurol Neurosurg Psychiatry. 2004;75(Suppl 2):ii43-50.PubMedPubMedCentral Rees JH. Paraneoplastic syndromes: when to suspect, how to confirm, and howto manage. J Neurol Neurosurg Psychiatry. 2004;75(Suppl 2):ii43-50.PubMedPubMedCentral
11.
go back to reference Tsoli M, Dimitriadis GK, Androulakis II, Kaltsas G, Grossman A. Paraneoplastic Syndromes Related to Neuroendocrine Tumors. 2020 Sep 26. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, Grossman A,Hershman JM, Hofland J, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Purnell J, Singer F, Stratakis CA, Trence DL, Wilson DP, editors. Endotext. South Dartmouth: MDText.com, Inc.; 2000&#8211. Tsoli M, Dimitriadis GK, Androulakis II, Kaltsas G, Grossman A. Paraneoplastic Syndromes Related to Neuroendocrine Tumors. 2020 Sep 26. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, Grossman A,Hershman JM, Hofland J, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Purnell J, Singer F, Stratakis CA, Trence DL, Wilson DP, editors. Endotext. South Dartmouth: MDText.com, Inc.; 2000&#8211.
12.
go back to reference Knochel JP. Neuromuscular manifestations of electrolyte disorders. Am J Med. 1982;72(3):521–35.CrossRef Knochel JP. Neuromuscular manifestations of electrolyte disorders. Am J Med. 1982;72(3):521–35.CrossRef
13.
go back to reference Zutt R, van der Kooi AJ, Linthorst GE, Wanders RJA, de Visser M. Rhabdomyolysis: Review of the literature. Neuromuscular Disorders Nmd. 2014;24(8):651-9. Zutt R, van der Kooi AJ, Linthorst GE, Wanders RJA, de Visser M. Rhabdomyolysis: Review of the literature. Neuromuscular Disorders Nmd. 2014;24(8):651-9.
14.
go back to reference Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(1):62–72.CrossRef Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361(1):62–72.CrossRef
15.
go back to reference Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians. Crit Care (London England). 2005;9(2):158–69.CrossRef Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians. Crit Care (London England). 2005;9(2):158–69.CrossRef
16.
go back to reference Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. European journal of internal medicine. 2007;18(2):90–100.CrossRef Giannoglou GD, Chatzizisis YS, Misirli G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. European journal of internal medicine. 2007;18(2):90–100.CrossRef
17.
go back to reference SG H. Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med. 2001;27(5):803–11.CrossRef SG H. Pathogenesis and treatment of renal dysfunction in rhabdomyolysis. Intensive Care Med. 2001;27(5):803–11.CrossRef
18.
go back to reference Parekh R, Care DA, Tainter CR. Rhabdomyolysis: advances in diagnosis and treatment. Emerg Med Pract. 2012;14(3):1–15 quiz 15.PubMed Parekh R, Care DA, Tainter CR. Rhabdomyolysis: advances in diagnosis and treatment. Emerg Med Pract. 2012;14(3):1–15 quiz 15.PubMed
Metadata
Title
A rare case of ectopic ACTH syndrome with rhabdomyolysis
Authors
Wei Qiang
Sucai Song
Tianjun Chen
Zhe Wang
Jun Feng
Jiaojiao Zhang
Hui Guo
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2021
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-021-00755-0

Other articles of this Issue 1/2021

BMC Endocrine Disorders 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.